India, Sept. 30 -- Avacta Group Plc. (AVCT.L), a clinical-stage life sciences company, reported a wider loss before tax for the first half of 2026, compared to the prior year.
The company has provided several clinical highlights on its lead programs.
Company Profile
Avacta is developing pre|CISION peptide drug conjugates or PDCs designed to release potent cancer payloads selectively in tumors using fibroblast activation protein or FAP. Its lead Next Generation program AVA6103, is a FAP-enabled controlled-release version of Exatecan being evaluated across several solid tumors.
First-Half Financial Highlights
Loss before tax increased to £18.85 million from £16.87 million a year earlier. The wider loss was primarily driven by h...